25 research outputs found
Effect of etanercept on insulin sensitivity in nine patients with psoriasis
Metabolic syndrome is associated to chronic low grade inflammation, characterized by increased levels of inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6). In particular, TNF-alpha causes a decrease in the insulin-stimulated kinases related to the early phases of the insulin cascade, thereby leading to insulin resistance. Etanercept is a human fusion protein used in the treatment of psoriasis and inflammatory arthritis. It blocks inflammatory response by interfering in the binding of TNF-alpha to its receptors. The aim of this case report study is to verify the effect of Etanercept on insulin sensitivity, lipid profile and inflammatory status in psoriatic patients. Nine psoriatic patients with stable, active, plaque type psoriasis were enrolled and treated with Etanercept for 24 weeks. We found an improvement in the metabolic assessment with a significant reduction of insulin plasma levels. In particular, this treatment allows to maintain their euglycemic state with lower insulin plasma levels, as confirmed by the improved Homeostasis Model Assessment (HOMA) index. We conclude that Etanercept, probably acting on inflammation, improves insulin sensitivity in psoriatic subjects
C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
Epub ahead of prin
Plasminogen activator inhibitor-1 plasma level increases with age in subjects with the 4G allele at position -675 in the promoter region.
Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes.
Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients
none12noneTesta R.; Olivieri F.; Bonfigli A.R.; Sirolla C.; Boemi M.; Marchegiani F.; Marra M.; Cenerelli S.; Antonicelli R.; Dolci A.; Paolisso G.; Franceschi C.Testa R.; Olivieri F.; Bonfigli A.R.; Sirolla C.; Boemi M.; Marchegiani F.; Marra M.; Cenerelli S.; Antonicelli R.; Dolci A.; Paolisso G.; Franceschi C
Circulating levels of soluble rage decline with aging and predict age-associated cardiac remodelling
Interleukin-6 is a determinant of PAI-1 levels in diabetic subjects with the 4 G allele at position -675 of the PAI-1 gene.
C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
Epub ahead of prin